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The initiation, propagation, and termination of signaling events controlling many cellular processes are determined by the level of tyrosine phosphorylation. Phosphotyrosine level, in turn, is maintained in an exquisite balance by the reciprocal activities of protein-tyrosine kinases and protein-tyrosine phosphatases (PTPases). To date, a large number of PTPases has been identified. Because balanced protein tyrosine phosphorylation is critical for the maintenance of cellular homeostasis, it is not surprising that PTPase malfunction has been linked to many human diseases (1) . Consequently, in those instances where PTPase activity is inappropriately high, PTPase inhibitors may provide a valuable new family of therapeutic agents. However, drug development targeted to PTPases was not seriously considered until recently. A major concern is that a PTPase may regulate multiple signaling pathways while at the same time, a single pathway may be controlled by several PTPases. Thus, PTPase inhibition may give rise to unwanted side effects. Significant progress has been made that is beginning to alleviate this concern.
For example, PTP1B has been suggested as a negative regulator of insulin signaling (2) (3) (4) . In addition to a role in insulin signaling, PTP1B is overexpressed in association with the expression of p185 c-erbB-2 in human breast and ovarian cancers (5, 6) , and PTP1B is capable of suppressing transformation by Neu (7) and v-Src (8) . Recently, PTP1B has been identified as the major PTPase that dephosphorylates and activates c-Src in several human breast cancer cell lines (9) . PTP1B is also capable of antagonizing signaling by the EGF receptor (10, 11) and the oncoprotein p210 bcr-abl (12) by directly dephosphorylating the EGF receptor and the p210 6 combinatorial library designed to target both the active site and an adjacent peripheral site in PTP1B. We also describe the development of an ELISA-based affinity selection procedure that was used to screen for potent PTP1B ligands. We have identified a highly potent PTP1B inhibitor (with a K i value of 2.4 nM) that exhibits several orders of magnitude selectivity in favor of PTP1B against a panel of PTPases. Our results demonstrate that it is feasible to achieve potency and selectivity for PTPase inhibition.
MATERIALS AND METHODS
General Procedures. All moisture-sensitive reactions were carried out in oven-dried glassware under a positive pressure of dry N 2 or Ar. DMA, DMF, DMSO, LHMDS, CH 2 Cl 2 , and THF for moisture-sensitive reactions were purchased from Aldrich in Sure/Seal TM bottles. All reactions were followed by TLC using E. Merck silica gel 60 F-254. Flash column chromatography was performed using J. T. Baker silica gel (230-400 mesh). BOP, DIC, HBTU, HOBt, piperidine, PyBOP, TFFH, and TSTU for peptide synthesis were purchased from Advanced ChemTech. The structures of new compounds were characterized by 1 H-NMR (300 7 in water for 2 hr. The resin was removed by filtration, and the remaining solution concentrated.
Dry diethyl ether was added and the precipitated peptides collected by centrifugation. The peptides were resuspended, washed twice with ether, dissolved in water, and purified by semipreparative reverse phase HPLC. All peptides were obtained in high purity (>95%) as analyzed by MALDI-TOF MS and analytical HPLC.
Synthesis of PTP1B
Ligand Library. The library was synthesized on a cystaminemodified Tentagel S NH 2 resin 1 using Fmoc chemistry (25) . pTyr was attached to the amino terminus of the resin-linked cystamine (8 g ). After Fmoc removal by two 5 min treatments with 30% piperidine in DMF, the resin was washed with DMF, CH 2 Cl 2 , isopropanol, and ether, and then the residual solvent removed in vacuo. The resin was distributed in 220 mg quantities into 20 mL polypropylene filtration tubes (Supelco) for coupling of the next component. (38) . A solution of the amino acid 37 (535 mg, 1.5 mmol) and NaHCO 3 (128 mg, 1.5 mmol) in water (5 mL) and dioxane (5 mL) was cooled in an ice bath and then treated with Fmoc-OSu (720 mg, 2.1 mmol)
Synthesis of Benzyl (2R,3S)-6-0xo-2,3-diphenyl-5-[(4-((diethylphosphono)difluoromethyl)benzyl)]-4-morpholinecarboxylate (36)
.
Synthesis of 4-[Diethylphosphono]difluoromethyl]-L-phenylalanine (37)
Synthesis of N-α-Fmoc-4-(Phosphonodifluoromethyl)-L-phenylalanine
in a small amount of dioxane (31) . After stirring for 3 hr at room temperature, the mixture was (35), VHR (36) , and MKP3 (37) were expressed in E. coli and purified as described previously.
The coding sequence of the catalytic domain (amino acid residues 1-288) of the human T cell PTPase (TCPTP) was a generous gift from Dr. Harry Charbonneau and TCPTP was expressed and purified as described (38) . Recombinant HePTP and the catalytic domains of SHP1 and SHP2 were expressed and purified as (His) 6 -fusion proteins. The catalytic domains of PTPα, LAR and CD45 were expressed and purified as recombinant glutathione S-transferase (GST) fusion proteins (39) . The intracellular fragment of PTPα, LAR and CD45 containing both of the PTPase domains was cleaved off the fusion protein as described using thrombin. The nonenzymatic hydrolysis of the substrate was corrected by measuring the control without addition of enzyme. After quenching, the amount of product p-nitrophenol was determined from the absorbance at 405 nm detected by a Spectra MAX340 microplate spectrophotometer (Molecular Devices) using a molar extinction coefficient of 18,000 M -1 cm -1 . The MichaelisMenten kinetic parameters were determined from a direct fit of the velocity versus substrate 
RESULTS AND DISCUSSION
As noted in the Introduction, biochemical and genetic studies suggest that PTP1B is a major modulator of insulin sensitivity and fuel metabolism. Thus PTP1B represents a potential therapeutic target for the treatment of Type II diabetes and obesity. Consequently, small molecules designed to inhibit PTP1B not only hold promise as pharmaceutical agents but also could function as probes for elucidating the roles of PTP1B in specific intracellular pathways involved in normal cellular processes. However, given the highly conserved nature of the PTPase active site (i.e., pTyr binding site), it has been assumed that it would be difficult to obtain specific inhibitors targeted to the active site of individual PTPases.
Our previous kinetic studies with pTyr-containing peptides and small molecule aryl phosphates showed that pTyr alone is not sufficient for high affinity binding by PTPases and residues surrounding the pTyr contribute to efficient substrate recognition (24, 26, (40) (41) (42) . In addition, the crystal structure of PTP1B/C215S complexed with low-molecular weight nonpeptidic substrates revealed, quite unexpectedly, the presence of a second aryl phosphatebinding site positioned adjacent to the active site (33) . This second site lies within a region that is not conserved among PTPases. As a consequence, this unanticipated observation suggested an alternative paradigm for the design of potent and specific PTP1B inhibitors; namely bidentate ligands that bind to both the active site and a unique adjacent peripheral site. In addition to the second aryl phosphate binding pocket, other sub-sites, positioned within the local vicinity of the active site, may also be conscripted for inhibitor design. For example, structures of PTPase in complex with pTyr-containing peptides and PTPase sequence alignments have suggested that the α1-β1 loop, the β5-β6 loop, the α5-α6 loop, and the WPD loop contain variable residues that may contribute to substrate specificity. Thus, our strategy to develop potent and PTPase-selective inhibitors for individual members of the PTPase family is to tether together two small ligands that are individually targeted to the active site and a unique proximal noncatalytic site. The rationale for the enhanced affinity of bidentate inhibitors is based on the principle of additivity of free energy of binding. The interaction of an inhibitor with two independent sites (e.g., pTyr site and a unique peripheral site) on one PTPase would be expected to confer exquisite specificity, since other PTPases may not possess an identical second site interaction. In the following, we describe a combinatorial approach for the identification of a highly potent and selective PTP1B
inhibitor that is able to simultaneously occupy both the active site and a unique second site on PTP1B.
Library Design and Construction. Our first-generation library was designed to contain two linked motifs, one targeted to the pTyr-binding catalytic site, and the other targeted to a unique adjacent noncatalytic site in PTP1B. Due to the demanding synthetic requirements associated with the preparation of nonhydrolyzable phosphonate analogs (vide infra), we felt it prudent to prepare a library of synthetically accessible phosphate-based derivatives. Once a high affinity lead from the latter is identified, it can then be converted into an inhibitor by replacing the phosphate moiety with a difluorophosphonate group. Since pTyr is the canonical ligand for
PTPase active site, we decided to structurally bias the library with pTyr in order to direct library members to the active site. A small array of structurally disparate aryl acids (A -H) ( Several library members were resynthesized on a larger scale using the same procedure in high yield and purity (about 90%) as assessed by HPLC and MOLDI-TOF MS analysis.
Assay Development. (43) and that the PTP1B/C215S mutant exhibits similar affinity for substrates as the wild-type enzyme (44) . We have also shown that the hexameric pTyr-containing peptide DADEpYL-amide is a high affinity PTP1B substrate (41, 44) . We prepared the biotinyl-caproic acid-DADEpYL-NH 2 peptide and found that it displayed kinetic parameters similar to those reported for the DADEpYL- There are several key points to be noted concerning the ELISA-based assay. First, since the reference ligand (biotinylated DADEpYL-NH 2 ) is known to bind to the PTP1B/C215S active site (18) , compounds that displace the reference ligand from PTP1B/C215S most likely bind to the active site as well. Second, since the catalytically inactive PTP1B/C215S binds ligands with equal potency as the wild-type enzyme, this assay furnishes a true assessment of the PTP1B
binding ability of the library members. Third, it is known that the invariant active site Cys residue is essential for PTPase catalytic activity (19) . Consequently, PTPases are prone to inactivation by oxidizing reagents, heavy metals, and alkylating compounds. This has presented a serious problem for the PTPase activity-based inhibitor screening projects in which hits are identified based on the ability of the compounds to reduce the PTPase activity. The substitution of the active site Cys by a Ser (e.g., PTP1B/C215S) renders the mutant PTPase less sensitive to oxidation and alkylation and thus will likely eliminate "false" positives due to interactions with the active site Cys that destroy the phosphatase activity. Finally, since the assay is ELISA-based, it can be easily implemented for high-throughput PTPase inhibitor discovery.
Identification of High-Affinity PTP1B Substrates. The ELISA-based screening protocol employed library members fixed at a 250 nM concentration and was performed in duplicate. This affinity-based screen allowed us to identify several lead compounds that effectively displace GST-PTP1B/C215S from the biotinylated DADEpYL-NH 2 peptide. Several key points are clear from the results graphically depicted in Figure 3 . First, the naturally occurring amino acids 11, 13, 21, 22, and 24 serve as the most effective linkers. For example, all the Asp-containing library members (21A -21H in Fig. 3c ) display significant inhibitory potency. Interestingly, these lead linkers are a mix of hydrophobic (11, 13, 24) and negatively charged (13, 21, 22 ) residues. The linker position is equivalent to the P-1 position (i.e. on the amino side of pTyr) in active sitedirected PTPase peptide/protein substrates. We have previously shown that PTP1B undergoes distinct conformational changes that allow it to accommodate either hydrophobic or negatively charged residues at the P-1 site (20) . Second, two of the most effective PTP1B ligands (21B and 24B) contain the same N-terminal element, the phosphorylated phenylacetic acid moiety B.
Finally, PTP1B is clearly quite sensitive to the structural nature of the N-terminal element given the fact that closely related elements (A and C) which differ by a single methylene group are less effective than the lead B.
In order to obtain a more accurate assessment of the affinity of these compounds for PTP1B/C215S, we measured the IC 50 values (compound concentrations that block 50% of the ELISA readout at 450 nm) of the lead compounds (21B and 24B) using 39 as a reference (Fig.   4 ). For comparison, we also measured the IC 50 values of compounds 4A and 4B, which were less effective than 21B and 24B in displacing biotinylated DADEpYL-NH 2 from PTP1B/C215S (Fig.   3 ). To avoid potential problems associated with the possible oxidation of the thiol tail in the library compounds, we resynthesized compounds 4A, 21B, and 24B without the thiol tail. Table   1 lists the ratio of the IC 50 values of the test compounds relative to that of the reference compound 39. Since 39 is an established competitive inhibitor for PTP1B with a K i value of 1 µM (39), this IC 50 ratio should reflect the true affinity of the test compounds for PTP1B (in units of µM). As can be seen from Table 1 , the presence of the thiol tail in the compounds does not affect the affinity of these compounds for PTP1B/C215S. It can be concluded that compounds 21B and 24B display binding affinities significantly higher than that of 39. In addition, compounds 21B and 24B also exhibit higher affinity for PTP1B than that of 4A and 4B, consistent with the ELISA results obtained at a single compound concentration (250 nM) (Fig.   3 ). Finally, although PTP1B can accommodate both Tyr (24) and Asp (21) at the P-1 position (20, 24) , it appears that in the context of the terminal element B, the linker Asp (21) is slightly favored over Tyr (24) .
Determination of K d Values.
The intrinsic fluorescence associated with the N terminus appended coumarin moiety in the 7-hydroxycoumarin-caproic acid-DADEpYL-NH 2 peptide was not significantly altered in the presence of GST-PTP1B/C215S. This property enabled us to determine the dissociation constant for the coumarin derivative via equilibrium dialysis using (44, 45, 47) . This has been attributed to a direct interaction between the fluorine atoms and PTP1B active site residues (47). Thus we decided to replace the ester oxygens in 21B with the difluoromethylene group.
The corresponding nonhydrolyzable analog (40, Fig. 4 ) of the high affinity phosphomonoester (21B) was prepared via solid phase synthesis using the difluorophosphonatecontaining derivatives 32 and 38. The hydrolytically resistant difluorophosphonate analog (32) of B was prepared from 4-(bromomethyl)phenylacetic acid as outlined in scheme II (39 particularly between PTP1B and TCPTP, has been a considerable challenge. As shown in Table   2 , compound 40 is highly selective for PTP1B, exhibiting a greater than three orders of magnitude preference for PTP1B versus nearly all phosphatases examined. More importantly, compound 40 also displays >10-fold selectivity in favor of PTP1B over TCPTP, which is the closest structural homologue of PTP1B (the catalytic domain of PTP1B (residues 1 -279) is 69% identical and 85% homologous to that of TCPTP). The high selectivity that is observed for compound 40 without any further optimization is quite impressive, considering the general lack of selectivity that has been observed for inhibitors of the PTPase family members. These results demonstrate that it is possible to achieve both potency and selectivity in PTPase inhibitor development. Scheme I .
Parallel synthesis of a library of compounds targeting both the active site and a unique adjacent site of PTP1B.
Scheme II .
Synthesis of the hydrolytically resistant difluorophosphonate analog (32) of B.
Scheme III .
Synthesis of the difluorophosphonate-containing unnatural amino acid 38. Scheme III
